Cyclerion Therapeutics, Inc. financial data

Symbol
CYCN on Nasdaq
Industry
Pharmaceutical Preparations
Location
301 Binney Street, Cambridge, MA
State of incorporation
MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 405 % +126%
Return On Equity -55.3 % +58.5%
Return On Assets -48.3 % +38.5%
Operating Margin -172 % +94.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.71M shares +10.8%
Common Stock, Shares, Outstanding 2.53M shares +3.51%
Entity Public Float 7.1M USD -62.2%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 2.53M shares +3.74%
Weighted Average Number of Shares Outstanding, Diluted 2.53M shares -9.33%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 194K USD
Research and Development Expense 254K USD -86%
General and Administrative Expense 5.87M USD -32.1%
Operating Income (Loss) -5.93M USD -578%
Nonoperating Income (Expense) 644K USD +65.6%
Net Income (Loss) Attributable to Parent -5.28M USD +51%
Earnings Per Share, Basic -1.76 USD/shares +83.9%
Earnings Per Share, Diluted -1.38 USD/shares +87.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.87M USD -68.5%
Accounts Receivable, after Allowance for Credit Loss, Current 44K USD
Other Assets, Current 11K USD -63.3%
Assets, Current 3.55M USD -64%
Other Long-term Investments 5.35M USD 0%
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 8.9M USD -41.5%
Accounts Payable, Current 304K USD -62.7%
Liabilities, Current 700K USD -70.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -268M USD -2.02%
Stockholders' Equity Attributable to Parent 8.2M USD -36.3%
Liabilities and Equity 8.9M USD -41.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.87M USD +69.9%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 20M shares 0%
Common Stock, Shares, Issued 2.71M shares +10.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.88M USD +69.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.87M USD -68.5%
Deferred Tax Assets, Valuation Allowance 82.4M USD +0.5%
Deferred Tax Assets, Gross 82.4M USD -0.71%
Property, Plant and Equipment, Gross 126K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 48.5M USD +3.09%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 500K shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 606K USD -71%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares